# Development of a Multi-species Vaccine for Prevention of Bacterial Otitis Media

> **NIH NIH R44** · CLARAMETYX BIOSCIENCE, INC. · 2022 · $1,207,921

## Abstract

Project Summary
 Otitis media (OM) is a spectrum of clinical entities that presents a tremendous global health burden; in fact,
OM is the most common infectious bacterial disease in children. Sequelae of OM include hearing impairment,
developmental and language delays, and even death, with nearly $5B spent annually in the US alone for
medical/surgical management and lost wages for working parents. The primary causative agents of OM are
Streptococcus pneumoniae (Spn), nontypeable Haemophilus influenzae (NTHI) and Moraxella catarrhalis
(Mcat). Spn was once the leading cause of acute OM (AOM); however, the introduction of pneumococcal
conjugate vaccines (PVCs) has significantly reduced Spn-associated AOM, thereby paving the way for NTHI
and non-vaccine Spn serotypes to dominate. Vaccination remains the most impactful and cost-effective way to
prevent OM, yet the ever-changing bacteriology of OM requires non-traditional approaches to resolve, and
ideally prevent, this global pediatric disease. Clarametyx Biosciences has developed the CMTX-301 vaccine
candidate to address all-pathogen OM. Immunization with CMTX-301 focuses the host immune response on
specific protective epitopes within components of the bacterial biofilm responsible for its structural stability.
When exposed to these antibodies, biofilms rapidly collapse with release of biofilm-resident bacteria. Given
that biofilms are the greatest defense mechanism against disease resolution, collapse of these protective
fortresses has proven to augment disease resolution in multiple diverse models of experimental disease,
including models of OM. By rapidly collapsing bacterial biofilms, vaccination with CMTX-301 allows the host’s
natural immune response to clear infection in a pathogen-agnostic manner. Data to date have demonstrated
the ability of CMTX-301 to induce collapse of biofilms formed by over 22 bacterial species (both Gram-negative
and -positive), including the high priority ESKAPEE pathogens and all three predominant otopathogens.
Preliminary evaluation of CMTX-301 has demonstrated its ability to prevent disease in a chinchilla viral-
bacterial superinfection model of ascending NTHI-induced OM. The program proposed herein will support
studies needed to optimize the research and development precursor of CMTX-301 into a clinically-viable
vaccine candidate. We have included studies designed to first evaluate formulations of CMTX-301 with FDA
approved adjuvants. Then, based on multiple characteristics and strengths of the induced immune response,
the lead and a backup formulation will be tested for relative protective efficacy in a chinchilla model of
experimental NTHI-induced OM model with expanded confirmatory evaluation in a rat model of Spn-induced
OM. We include evaluation of dose regimen and schedule as part of our program. Additionally, the lead
candidate will undergo safety evaluation and GMP manufacturing, as needed to support an Investigational
New Drug application with the FDA. Th...

## Key facts

- **NIH application ID:** 10323174
- **Project number:** 1R44DC019874-01
- **Recipient organization:** CLARAMETYX BIOSCIENCE, INC.
- **Principal Investigator:** Charles C. McOsker
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1,207,921
- **Award type:** 1
- **Project period:** 2022-01-01 → 2024-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10323174

## Citation

> US National Institutes of Health, RePORTER application 10323174, Development of a Multi-species Vaccine for Prevention of Bacterial Otitis Media (1R44DC019874-01). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10323174. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*